375 related articles for article (PubMed ID: 16805719)
1. Bortezomib for multiple myeloma.
Popat R; Joel S; Oakervee H; Cavenagh J
Expert Opin Pharmacother; 2006 Jul; 7(10):1337-46. PubMed ID: 16805719
[TBL] [Abstract][Full Text] [Related]
2. Current status of bortezomib in the treatment of multiple myeloma.
Cavo M
Curr Hematol Malig Rep; 2007 May; 2(2):128-37. PubMed ID: 20425361
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
4. [Proteasome inhibitors].
Alexandre J
Rev Med Interne; 2005 Oct; 26(10):812-5. PubMed ID: 16129520
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
7. The proteasome: a novel target for anticancer therapy.
Montagut C; Rovira A; Albanell J
Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
[TBL] [Abstract][Full Text] [Related]
8. Cancer research. Taking garbage in, tossing cancer out?
Garber K
Science; 2002 Jan; 295(5555):612-3. PubMed ID: 11809952
[No Abstract] [Full Text] [Related]
9. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
Cheriyath V; Jacobs BS; Hussein MA
Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitor therapy in multiple myeloma.
Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC
Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343
[TBL] [Abstract][Full Text] [Related]
11. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
Schwartz R; Davidson T
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
[TBL] [Abstract][Full Text] [Related]
13. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
Tobinai K
Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
[No Abstract] [Full Text] [Related]
14. Proteasome inhibition for treatment of multiple myeloma: clinical update.
Stadtmauer EA
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
16. The potential of proteasome inhibitors in cancer therapy.
Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
[TBL] [Abstract][Full Text] [Related]
17. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.
Kim GP; Mahoney MR; Szydlo D; Mok TS; Marshke R; Holen K; Picus J; Boyer M; Pitot HC; Rubin J; Philip PA; Nowak A; Wright JJ; Erlichman C
Invest New Drugs; 2012 Feb; 30(1):387-94. PubMed ID: 20839030
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition in multiple myeloma.
Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
Cavo M
Leukemia; 2006 Aug; 20(8):1341-52. PubMed ID: 16810203
[TBL] [Abstract][Full Text] [Related]
20. First proteasome inhibitor approved for multiple myeloma.
Twombly R
J Natl Cancer Inst; 2003 Jun; 95(12):845. PubMed ID: 12813164
[No Abstract] [Full Text] [Related]
[Next] [New Search]